Home' Australian Pharmacist : Australian Pharmacist October 2015 Contents Australian Pharmacist October 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer.
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD credits.
PSA members can answer online at www.psa.org.au.
• Login to submit your answers online. If you
do not have member access details, you can
request them via a link from the login page.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers online before
1 December 2017 at www.psa.org.au
and receive automatic feedback.
1. Which ONE of the following issues
encountered in antidepressant
treatments may partly reflect
a) Patients show delayed response to
b) Patients show limited or no response to
c) Patients become refractory to different
d) Patients experience side effects.
e) All of the above.
2. Which ONE of the following
factors is LEAST likely to
affect a patient’s response to
a) Transporter gene variants.
b) Metabolism-related gene variants.
c) Inflammation-related gene variants.
d) Target-related gene variants.
e) Multi-drug-gene interactions.
3. Which of the following drugs is
LEAST strongly affected by CYP2D6
4. Which of the following is NOT
a potential benefit of applying
pharmacogenomics to inform care of
a) Increased tolerance.
b) Increased testing costs.
c) Decreased sick leave.
d) Increased adherence.
e) Increased remission rates.
16. Nebert DW, Wikvall K, Miller WL. Human cytochromes P450
in health and disease. Philos Trans R Soc Lond B Biol Sci
17. Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1
genotype and PGP expression, function and therapeutic
drug response: a critical review and recommendations for
future research. Pharmacogenomics J 2007;7(3):154–79.
18. Haufroid V, Hantson P. CYP2D6 genetic polymorphisms
and their relevance for poisoning due to amfetamines,
opioid analgesics and antidepressants. Clin Toxicol (Phila)
19. Jornil J, Nielsen TS, Rosendahl I, et al. A poor metabolizer
of both CYP2C19 and CYP2D6 identified by mechanistic
pharmacokinetic simulation in a fatal drug poisoning
case involving venlafaxine. Forensic Sci Int 2013;226(1–
20. Koski A, Sistonen J, Ojanpera I, et al. CYP2D6 and CYP2C19
genotypes and amitriptyline metabolite ratios in a series
of medicolegal autopsies. Forensic Sci Int 2006;158(2–
21. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death
in a child with cytochrome P-450 2D6 genetic deficiency. J
Child Adolesc Psychopharmacol 2000;10(1):27–34.
22. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics
Implementation Consortium guideline for CYP2D6 and
CYP2C19 genotypes and dosing of tricyclic antidepressants.
Clin Pharmacol Ther 2013;93(5):402–8 .
23. PharmGKB. Clinical Pharmacogenetics Implementation
Consortium dosing guideline for amitriptyline and
CYP2C19, CYP2D6. 2015. At: www.pharmgkb.org/drug/
24. PharmGKB. Clinical Pharmacogenetics Implementation
Consortium dosing guideline for SSRIs. 2015. At: www.
25. Spina E, Santoro V, D ’Arrigo C. Clinically relevant
pharmacokinetic drug interactions with second-generation
antidepressants: an update. Clin Ther 2008;30(7):1206–27.
26. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions
and pharmacogenomics in the treatment of breast cancer
and depression. Am J Psychiatry 2008;165(10):1251–5 .
27. Park SH, Wackernah RC, Stimmel GL. Serotonin
syndrome: is it a reason to avoid the use of tramadol with
antidepressants? J Pharm Pract 2014:27(1);71–8 .
28. Keers R, Uher R, Huezo-Diaz P, et al. Interaction between
serotonin transporter gene variants and life events predicts
response to antidepressants in the GENDEP project.
Pharmacogenomics J 2011;11(2):138–45.
29. Reynolds GP, McGowan OO, Dalton CF. Pharmacogenomics
in psychiatry : the relevance of receptor and transporter
polymorphisms. Br J Clin Pharmacol 2014;77(4):654–72.
30. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of
serotonin transporter gene promoter polymorphism
(5-HTTLPR) association with selective serotonin reuptake
inhibitor efficacy in depressed patients. Mol Psychiatry
31. Myung W, Lim SW, Kim S, et al. Serotonin transporter
genotype and function in relation to antidepressant
response in Koreans. Psychopharmacology (Berl)
32. Lin JY, Jiang MY, Kan ZM, et al. Influence of 5-HTR2A genetic
polymorphisms on the efficacy of antidepressants in the
treatment of major depressive disorder: a meta-analysis. J
Affect Disord 2014;168:430–8 .
33. Artigas, F. Future directions for serotonin and
antidepressants. ACS Chem Neurosci 2013;4(1):5–8 .
34. Perroud N, Aitchison KJ, Uher R, et al. Genetic
predictors of increase in suicidal ideation during
antidepressant treatment in the GENDEP project.
35. Hodgson K, Uher R, Crawford AA, et al. Genetic predictors
of antidepressant side effects: a grouped candidate
gene approach in the Genome-Based Therapeutic Drugs
for Depression (GENDEP) study. J Psychopharmacol
36. Altar CA, Carhart JM, Allen JD, et al. Clinical validity:
Combinatorial pharmacogenomics predicts antidepressant
responses and healthcare utilizations better than single
gene phenotypes. Pharmacogenomics J 2015;1–9 .
37. Winner JG, Carhart JM, Altar CA, et al. Combinatorial
pharmacogenomic guidance for psychiatric medications
reduces overall pharmacy costs in a 1 year prospective
evaluation. Curr Med Res Opin 2015:1–11.
38. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and
rationale for consensus definitions of terms in major
depressive disorder. Remission, recovery, relapse, and
recurrence. Arch Gen Psychiatry 1991;48(9):851–5 .
39. Nierenberg AA, DeCecco LM. Definitions of antidepressant
treatment response, remission, nonresponse, partial
response, and other relevant outcomes: a focus on
treatment-resistant depression. J Clin Psychiatry
Links Archive Australian Pharmacist September 2015 Australian Pharmacist November 2015 Navigation Previous Page Next Page